BPC-157/TB-500
500 mcg · Daily
Evidence
- Human Studies
- 3
- Animal Studies
- 45
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — no long-term human safety data published
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
BPC-157 is a synthetic fragment derived from a protein found in gastric juice, studied for effects on angiogenesis and tissue repair signaling. TB-500 is a synthetic fragment of thymosin beta-4, studied for actin regulation involved in cell migration and wound healing.
Common Protocols
- 250–500 mcg once or twice daily, injected near the site of injury or subcutaneously
- Typical research cycles run 4–8 weeks
Side Effects
- Injection site irritation
- Mild fatigue reported anecdotally
- Limited formal adverse-event data in humans
Interactions
- Little formal drug-interaction research exists; caution advised when combined with other experimental compounds
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution; use within 2–4 weeks for best stability
Research Links
0.5mg BPC-157 + 0.5mg TB-500 combined, separate syringe from NAD+